RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia

Papaemmanuil, E. et al. (2014) RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia. Nature Genetics, 46(2), pp. 116-125. (doi: 10.1038/ng.2874) (PMID:24413735) (PMCID:PMC3960636)

Full text not currently available from Enlighten.

Abstract

The ETV6-RUNX1 fusion gene, found in 25% of childhood acute lymphoblastic leukemia (ALL) cases, is acquired in utero but requires additional somatic mutations for overt leukemia. We used exome and low-coverage whole-genome sequencing to characterize secondary events associated with leukemic transformation. RAG-mediated deletions emerge as the dominant mutational process, characterized by recombination signal sequence motifs near breakpoints, incorporation of non-templated sequence at junctions, ∼30-fold enrichment at promoters and enhancers of genes actively transcribed in B cell development and an unexpectedly high ratio of recurrent to non-recurrent structural variants. Single-cell tracking shows that this mechanism is active throughout leukemic evolution, with evidence of localized clustering and reiterated deletions. Integration of data on point mutations and rearrangements identifies ATF7IP and MGA as two new tumor-suppressor genes in ALL. Thus, a remarkably parsimonious mutational process transforms ETV6-RUNX1–positive lymphoblasts, targeting the promoters, enhancers and first exons of genes that normally regulate B cell differentiation.

Item Type:Articles
Additional Information:This work was supported by the Kay Kendall Leukaemia Fund (KKLF; grant reference KKL407), Leukemia and Lymphoma Research (grant reference 11021) and the Wellcome Trust (grant reference 077012/Z/05/Z). P.J.C. is personally funded through a Wellcome Trust Senior Clinical Research Fellowship (grant reference WT088340MA). P.V.L. is supported by a postdoctoral research fellowship from Research Foundation–Flanders (FWO). S.N.-Z. is a Wellcome Trust Intermediate Clinical Fellow (grant reference WT100183MA). F.W.v.D. is funded by KKLF (grant reference KKL417). J.Z. is supported by University Hospital Motol (grant MH-CR DRO 00064203).
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Cooke, Dr Susie and Marshall, Mr John
Authors: Papaemmanuil, E., Rapado, I., Li, Y., Potter, N. E., Wedge, D. C., Tubio, J., Alexandrov, L. B., Van Loo, P., Cooke, S. L., Marshall, J., Martincorena, I., Hinton, J., Gundem, G., van Delft, F. W., Nik-Zainal, S., Jones, D. R., Ramakrishna, M., Titley, I., Stebbings, L., Leroy, C., Menzies, A., Gamble, J., Robinson, B., Mudie, L., Raine, K., O'Meara, S., Teague, J. W., Butler, A. P., Cazzaniga, G., Biondi, A., Zuna, J., Kempski, H., Muschen, M., Ford, A. M., Stratton, M. R., Greaves, M., and Campbell, P. J.
College/School:College of Medical Veterinary and Life Sciences > School of Cancer Sciences
Journal Name:Nature Genetics
Publisher:Nature Publishing Group
ISSN:1061-4036
ISSN (Online):1546-1718
Published Online:12 January 2014

University Staff: Request a correction | Enlighten Editors: Update this record